Patents by Inventor Guillaume DUVEY

Guillaume DUVEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
    Publication number: 20220363664
    Abstract: The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 (“mGluR7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably mGluR7 subtype of metabotropic glutamate receptors, is involved.
    Type: Application
    Filed: July 6, 2022
    Publication date: November 17, 2022
    Applicant: PRAGMA Therapeutics
    Inventors: Guillaume DUVEY, Sylvain CELANIRE
  • Heterocyclic compounds as modulators of mGluR7
    Patent number: 11414395
    Abstract: The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (m Glu R), preferably of the metabotropic glutamate receptor subtype 7 (“m Glu R7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably m Glu R7 subtype of metabotropic glutamate receptors, is involved.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 16, 2022
    Assignee: Pragma Therapeutics
    Inventors: Guillaume Duvey, Sylvain Celanire
  • NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
    Publication number: 20200231563
    Abstract: The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (m Glu R), preferably of the metabotropic glutamate receptor subtype 7 (“m Glu R7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably m Glu R7 subtype of metabotropic glutamate receptors, is involved.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 23, 2020
    Inventors: Guillaume DUVEY, Sylvain CELANIRE